- Home
- WTTR vs CVAC Comparison
WTTR vs CVAC Comparison
Compare WTTR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTTR
- CVAC
- Stock Information
- Founded
- WTTR 2016
- CVAC 2000
- Country
- WTTR United States
- CVAC Germany
- Employees
- WTTR N/A
- CVAC N/A
- Industry
- WTTR Oilfield Services/Equipment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- WTTR Energy
- CVAC Health Care
- Exchange
- WTTR Nasdaq
- CVAC Nasdaq
- Market Cap
- WTTR 1.1B
- CVAC 1.2B
- IPO Year
- WTTR 2017
- CVAC 2020
- Fundamental
- Price
- WTTR $10.10
- CVAC $5.39
- Analyst Decision
- WTTR Strong Buy
- CVAC Hold
- Analyst Count
- WTTR 3
- CVAC 3
- Target Price
- WTTR $15.00
- CVAC $6.83
- AVG Volume (30 Days)
- WTTR 1.2M
- CVAC 382.8K
- Earning Date
- WTTR 11-04-2025
- CVAC 11-11-2025
- Dividend Yield
- WTTR 2.75%
- CVAC N/A
- EPS Growth
- WTTR N/A
- CVAC N/A
- EPS
- WTTR 0.32
- CVAC 1.01
- Revenue
- WTTR $1,458,995,000.00
- CVAC $599,540,810.00
- Revenue This Year
- WTTR N/A
- CVAC N/A
- Revenue Next Year
- WTTR N/A
- CVAC $23.83
- P/E Ratio
- WTTR $31.62
- CVAC $5.34
- Revenue Growth
- WTTR N/A
- CVAC 675.15
- 52 Week Low
- WTTR $7.20
- CVAC $2.37
- 52 Week High
- WTTR $15.14
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- WTTR 55.13
- CVAC 45.21
- Support Level
- WTTR $9.89
- CVAC $5.35
- Resistance Level
- WTTR $10.72
- CVAC $5.44
- Average True Range (ATR)
- WTTR 0.33
- CVAC 0.03
- MACD
- WTTR -0.12
- CVAC -0.00
- Stochastic Oscillator
- WTTR 34.60
- CVAC 23.73
About WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.